High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery.
Etienne BuscailCatherine Alix-PanabièresPascaline QuincyThomas CauvinAlexandre ChauvetOlivier DegrandiCharline CaumontSéverine VerdonIsabelle LamrissiIsabelle MoranvillierCamille BuscailMarion MartyChristophe LaurentVéronique VendrelyFrançois Moreau-GaudryAurélie BedelSandrine DabernatLaurence ChichePublished in: Cancers (2019)
This study is the first to evaluate combined CTC and exosome detection to diagnose resectable pancreatic cancers. Liquid biopsy combining several biomarkers could provide a rapid, reliable, noninvasive decision-making tool in early, potentially curable pancreatic cancer. Moreover, the prognostic value could select patients eligible for neoadjuvant treatment before surgery. This exploratory study deserves further validation.
Keyphrases
- circulating tumor cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- decision making
- stem cells
- prognostic factors
- mesenchymal stem cells
- coronary artery bypass
- squamous cell carcinoma
- radiation therapy
- locally advanced
- rectal cancer
- ultrasound guided
- loop mediated isothermal amplification
- combination therapy